Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience

BACKGROUND AND OBJECTIVES: Pakistan is among leading countries of world in prevalence of chronic hepatitis C Daclatasvir plus sofosbuvir is recommended for treatment of CHC. The purpose of study was to determine the sustained virological response in patients with chronic viral hepatitis C genotype 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Zamir, Shah, Syed Muhammad Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500802/
https://www.ncbi.nlm.nih.gov/pubmed/31086524
http://dx.doi.org/10.12669/pjms.35.2.637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500802/
https://www.ncbi.nlm.nih.gov/pubmed/31086524
http://dx.doi.org/10.12669/pjms.35.2.637

Ejemplares similares